Article Commentary: Can Antiviral Therapy for Chronic Hepatitis B Enhance the Progression to Hepatocellular Carcinoma?

Bosch F.X. , Ribes J. , Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271–285.

Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–543.

Thomas M.B. , Zhu A.X. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892–2899.

Hino O. , Kajino K. , Umeda T. , Arakawa Y. Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 2002; 37: 883–887.

Chen C.J. , Yang H.I. , Su J. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.

Chan H.L. , Hui A.Y. , Wong M.L. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494–1498.

Ding X. , Mizokami M. , Yao G. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology 2001; 44: 43–47.

Orito E. , Ichida T. , Sakugawa H. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34: 590–594.

Carman W.F. , Jacyna M.R. , Hadziyannis S. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 334: 588–591.

Akahane Y. , Yamanaka T. , Suzuki H. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99: 1113–1119.

Nakamoto Y. , Guidotti L.G. , Kuhlen C.V. , Fowler P. , Chisari F.V. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341–350.

Brechot C. , Pourcel C. , Louise A. , Rain B. , Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980; 286: 533–535.

Paterlini-Brechot P. , Saigo K. , Murakami Y. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003; 22: 3911–3916.

Brechot C. , Thiers V. , Kremsdorf D. , Nalpas B. , Pol S. , Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology 2001; 34: 194–203.

Dandri M. , Burda M.R. , Burkle A. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology 2002; 35: 217–223.

Bouchard M.J. , Schneider R.J. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78: 12725–12734.

Soussan P. , Tuveri R. , Nalpas B. The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J Hepatol 2003; 38: 343–348.

Caselmann W.H. , Meyer M. , Kekule A.S. , Lauer U. , Hofschneider P.H. , Koshy R. A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci U S A 1990; 87: 2970–2974.

Kekule A.S. , Lauer U. , Meyer M. , Caselmann W.H. , Hofschneider P.H. , Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990; 343: 457–461.

Schluter V. , Meyer M. , Hofschneider P.H. , Koshy R. , Caselmann W.H. Integrated hepatitis B virus X and 3’ truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 1994; 9: 3335–3344.

Locarnini S.A. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998; 27: 294–297.

Yeh C.T. , Chien R.N. , Chu C.M. , Liaw Y.F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318–1326.

Chien R.N. , Yeh C.T. , Wang P.N. Acute leukaemia in chronic hepatitis B patients with lamivudine therapy. Int J Clin Pract 2004; 58: 1088–1091.

Yatsuji H. , Noguchi C. , Hiraga N. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006; 50: 3867–3874.

Warner N. , Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48: 88–98.

Tatti K.M. , Korba B.E. , Stang H.L. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antiviral Res 2002; 55: 141–150.

Lacombe K. , Ollivet A. , Gozlan J. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006; 20: 2229–2231.

Rhee S.S. Microbiology Review. US Food and Drug Administration Centre For Drug Evaluation And Research 2006. (Updated 23 October 2006. Accessed 10 February 2009.) Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.

Yoo B.C. , Kim J.H. , Chung Y.H. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172–1178.

Durantel D. , Brunelle M.N. , Gros E. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 2005; 34 Suppl 1: S34–S43.

Qi X. , Xiong S. , Yang H. , Miller M. , Delaney W.E.I. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355–362.

Hildt E. , Hofschneider P.H. The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Recent Results Cancer Res 1998; 154: 315–329.

Bruss V. , Lu X. , Thomssen R. , Gerlich W.H. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J 1994; 13: 2273–2279.

Ostapchuk P. , Hearing P. , Ganem D. A dramatic shift in the transmembrane topology of a viral envelope glycoprotein accompanies hepatitis B viral morphogenesis. EMBO J 1994; 13: 1048–1057.

Prange R. , Streeck R.E. Novel transmembrane topology of the hepatitis B virus envelope proteins. EMBO J 1995; 14: 247–256.

Hildt E. , Saher G. , Bruss V. , Hofschneider P.H. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator. Virology 1996; 225: 235–239.

Hildt E. , Urban S. , Hofschneider P.H. Characterization of essential domains for the functionality of the MHBst transcriptional activator and identification of a minimal MHBst activator. Oncogene 1995; 11: 2055–2066.

Lauer U. , Weiss L. , Hofschneider P.H. , Kekule A.S. The hepatitis B virus pre-S/S(t) transactivator is generated by 3’ truncations within a defined region of the S gene. J Virol 1992; 66: 5284–5289.

Natoli G. , Avantaggiati M.L. , Balsano C. Characterization of the hepatitis B virus preS/S region encoded transcriptional transactivator. Virology 1992; 187: 663–670.

Li J. , Lee A.S. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006; 6: 45–54.

Shuda M. , Kondoh N. , Imazeki N. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 2003; 38: 605–614.

Lai M.W. , Yeh C.T. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008; 13: 875–879.

Chisari F.V. , Klopchin K. , Moriyama T. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145–1156.

Liaw Y.F. , Sung J.J. , Chow W.C. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–1531.